Dipti Kanabar, PhD.

Determined and well-rounded individual with over 2 years of experience working as a scientist in the early drug discovery industry. Possessing sharp and focused skills in handling drug discovery projects, with expertise in chemistry and biology. Fundamentally sound medicinal chemistry scientist with 7 years of experience in small molecule drug development, serving as an investigator or co-investigator on numerous projects addressing various illnesses such as cancer, infectious diseases, Alzheimer\'s disease, and more. Demonstrating a strong understanding of disease targets and biological assays to interpret medicinal chemistry data, along with knowledge in computer-aided drug design. Exceptional written and oral communication skills, coupled with a collaborative nature, have resulted in 17 publications and 12 posters presented at conferences. Recognized as a research scientist, team builder, project leader, program support, and technical operations expert who excels in deadline-driven or fast-paced environments. A unique blend of key roles as a scientist, analyst, project manager, and group leader with a solution and result-oriented approach.

• I attended the Residential Medicinal Chemistry Program at Drew University, NJ. (June 2023)
• Attended a master class for fundamentals of Pharmacokinetics in drug discovery. (Feb 2024)
• American Chemical Society, Member (2017 - Present)
• NY ACS Chemagination Competition, Judge (2018 - 2022)

• Specificity studies of small molecule inhibitors targeting the ankyrin-repeat oncoprotein gankyrin, PROTEIN SCIENCE, 32, 12, 2023-12-01, 111 RIVER ST, HOBOKEN, NJ, 07030-5774, USA
• Targeting the Oncoprotein Gankyrin with Small Molecules to Alter its 3D Global Fold, PROTEIN SCIENCE, 32, 12, 2023-12-01, 111 RIVER ST, HOBOKEN, NJ, 07030-5774, USA
• 3-minute thesis (3MT) presentation at AAPS (American Association of Pharmaceutical Science) St. John's University, student chapter, 2022-04-01
• Second generation small molecule inhibitors of gankryin for the treatment of pediatric liver cancer, SIOP Annual conference, 2022-04-01, Seattle, WA, USA, Poster
• Optimizing triazole and sulfonate ester of cjoc42 to improve anti-cancer activity and enhanced gankyrin binding, 259th ACS National Meeting and Exposition, 2020-03-01, Philadelphia, PA, USA, Poster
• Efforts to improve the cjoc42 scaffold for binding gankyrin and enhanced water solubility, 259th ACS National Meeting and Exposition, 2020-03-01, Philadelphia, PA, USA, Poster
• Optimizing the aryl substitutions of cjoc42 for enhanced gankyrin binding and anti-cancer activity, 259th ACS National Meeting and Exposition, 2020-03-01, Philadelphia, PA, USA, Poster
• Development of conformationally constrained cjoc42 derivatives for binding gankyrin, 259th ACS National Meeting and Exposition, 2020-03-01, Philadelphia, PA, USA, Poster
• Development of Small Molecule- and Peptide-based Probes for Targeting Gankyrin, 256th ACS National Meeting and Exposition, 2018-08-01, Boston, MA, USA, Poster
• Development of Small Molecule- and Peptide-based Probes for Targeting Gankyrin, 10th Charles I Jarowski Symposium in Industrial Pharmacy, 2018-06-01, Queens, NY, USA, Poster
• Development of Small Molecule- and Peptide-based Probes for Targeting Gankyrin, St. John's University Research Month, 2018-01-01

• Structural modification of the propyl linker of cjoc42 in combination with sulfonate ester and triazole replacements for enhanced gankyrin binding and anti-proliferative activity, Bioorganic & Medicinal Chemistry, 110, 117836, 2024-01-01
• Exploring the enhanced stability and therapeutic efficacy of Sorafenib-Cyclodextrin inclusion complex, Journal of Molecular Liquids, 401, 124701, 2024-01-01
• Synthesis and evaluation of 2, 5-substituted pyrimidines as small-molecule gankyrin binders, Future Medicinal Chemistry, 16, 3, 239-251, 2024-01-01
• Poly vinyl pyrrolidone (PVP) based inhaled delivery carriers for olaparib for non-small cell lung cancer (NSCLC) treatment, Journal of Drug Delivery Science and Technology, 104767, 2023-01-01
• Second generation small molecule inhibitors of gankryin for the treatment of pediatric liver cancer, Cancers, 14, 13, 3068, 2022-01-01
• Small Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer, Journal of Medicinal Chemistry, 65, 13, 8975-8997, 2022-01-01
• Bioinspired particle engineering for non-invasive inhaled drug delivery to the lungs, Materials Science and Engineering: C, 128, 112324, 2021-01-01
• Identification of Novel Gankyrin Binding Scaffolds by High Throughput Virtual Screening, Bioorganic & Medicinal Chemistry Letters, 128043-128043, 2021-01-01
• Bypassing P-glycoprotein Mediated Efflux of Afatinib by Cyclodextrin Complexation - Impact on Intestinal Absorption and Anti-Cancer Activity, J. Mol. Liq.
• Exploring gankyrin's role in cancer development and its potential as a therapeutic target, Future Med. Chem.
• Enhanced Stability, Permeation and Anti-Cancer Efficacy of Celastrol-β-Cyclodextrin Inclusion Complex, J. Mol. Liq.
• Optimizing the Aryl Triazole of cjco42 for Enhanced Gankyrin Binding and Anticancer Activity, Bioorg. Med. Chem. Lett., 30, 127372, 2020-01-01
• Cyclodextrin Complexation for Enhanced Stability and Non-invasive Pulmonary Delivery of Resveratrol - Applications in Non-Small Cell Lung Cancer Treatment, AAPS PharmSciTech., 21, 183, 2020-01-01
• Structural Modification of the Aryl Sulfonate Ester of cjoc42 for Enhanced Gankyrin Binding and Anti-cancer Activity, Bioorg. Med. Chem. Lett., 30, 126889, 2020-01-01
• Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-small Cell Lung Cancer, Pharm. Res., 37, 67, 2020-01-01
• Cyclodextrin Modified Erlotinib Loaded PLGA Nanoparticles for Improved Therapeutic Efficacy against Non-Small Cell Lung Cancer, Int. J. Biol. Macromol., 122, 338-347, 2018-01-01
• Nintedanib-Cyclodextrin Complex to Improve Bio-Activity and Intestinal Permeability, Carbohydr. Polym., 204, 68-77, 2018-01-01